PALO ALTO, Calif., Feb. 6, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced its Eclipse™ treatment planning system and TrueBeam® treatment system have been named Category Leaders in the 2019 Best in KLAS: Software and Services Report by KLAS, an independent research firm specializing in monitoring and reporting on the performance of healthcare vendors. Eclipse was ranked first in Oncology Treatment Planning and TrueBeam was ranked first in Radiation Therapy.
Named a Category Leader for the sixth year in a row, Eclipse software creates an optimized radiotherapy treatment plan based on a physician's prescription, and information about the size, shape, and location of the tumor to be treated with radiation. The Eclipse software incorporates unique features such as HyperArc™ high definition radiotherapy (HDRT) treatment planning for intracranial radiosurgery, RapidPlan™ knowledge-based planning, and multi-criteria optimization (MCO). RapidPlan is designed to simplify and accelerate the planning process for sophisticated cancer treatments like stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT), and RapidArc® radiotherapy. MCO allows clinicians to explore what happens when different clinical criteria are varied, such as the degree to which particular organs are spared versus coverage of the targeted tumor.
According to the 2019 Best in KLAS report, Eclipse received the highest average score for overall performance. In comments posted on KLASresearch.com, a physicist using the software said, "Eclipse is really easy to use for the physicists. We do all of our treatment planning in Eclipse, and it integrates well with our Varian equipment." A chief information officer added, "Eclipse continues to be the gold standard in radiation oncology for treatment planning." To view the Oncology Treatment Planning Category Leaders report, visit https://klasresearch.com/best-in-klas-ranking/oncology-treatment-planning/2019/221.
KLAS created the Radiation Therapy category in 2018, and Varian's TrueBeam has now been named Category Leader both years of the ranking. The TrueBeam family of medical linear accelerators incorporate numerous technical innovations that dynamically synchronize imaging, patient positioning, motion management, and treatment delivery during a radiotherapy or radiosurgery procedure. TrueBeam also received the highest average score for overall performance in the 2019 Best in KLAS report.
In comments posted on KLASresearch.com, a physicist who uses the treatment system stated, "The TrueBeam has much faster treatment times than our other machine." A Varian customer who is a manager added, "TrueBeam makes it easier to treat a broad spectrum of patients. The system can help us treat simple patients and complex patients." To view the Radiation Therapy Category Leaders report visit https://klasresearch.com/best-in-klas-ranking/radiation-therapy/2019/151
"We are honored once again to have both Eclipse and TrueBeam recognized as a Category Leaders by KLAS," said Dow Wilson, president and chief executive officer, Varian. "The Varian team values its close partnerships with oncology clinicians around the world as we work together to better understand changing cancer care needs and leveraging that insight to guide us in developing and delivering best-in-class solutions for fighting cancer and moving us closer to a world without fear of cancer."
The 2019 Best in KLAS report, published at the end of January, ranks healthcare vendors and their solutions by the professionals who use them—healthcare providers. For a full list of Best in KLAS winners, Global (Non-U.S.) Best in KLAS winners, and Category Leaders, visit https://klasresearch.com/report/2019-best-in-klas-software-services/1473
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Director, Global Public Relations
+1 (650) 424-5630
Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163